* Sunshine Biopharma Inc reported a quarterly adjusted loss of $9.94 per share for the quarter ended in June. The lone analyst forecast for the quarter was for a loss of $7.40 per share.
* Revenue was $9.30 million; analysts expected $9.00 million.
* Sunshine Biopharma Inc's reported EPS for the quarter was a loss of $9.94.
* The company reported a quarterly loss of $494.3 thousand.
* Sunshine Biopharma Inc shares had fallen by 65.0% this quarter and lost 99.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Sunshine Biopharma Inc is $300.00 This summary was machine generated from LSEG data August 19 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -7.40 -9.94 Missed
Mar. 31 2024 -20.80 -40.00 Missed
Dec. 31 2023 -60.00 -1.00 hundred Missed
Sep. 30 2023 -1.20 hundred -80.00 Beat
Comments